Activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC α1
subunit. Inhibits platelet aggregation (IC50
= 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC50
= 0.30 μ
M). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
NO-independent regulatory site on soluble guanylate cyclase.
Stasch et al.
The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways.
Joshi et al.
Discovery of Riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Mittendorf et al.